CORT – corcept therapeutics incorporated (US:NASDAQ)
Stock Stats
News
It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder [Seeking Alpha]
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer [Yahoo! Finance]
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Piper Sandler from $128.00 to $131.00. They now have an "overweight" rating on the stock.
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? [Yahoo! Finance]
Form 4 CORCEPT THERAPEUTICS For: Apr 10 Filed by: Swisher Daniel N JR
Form 144 CORCEPT THERAPEUTICS Filed by: Swisher Daniel N JR
Form 4 CORCEPT THERAPEUTICS For: Mar 31 Filed by: Maduck Sean
Form 4 CORCEPT THERAPEUTICS For: Mar 31 Filed by: Lyon Joseph Douglas
Form 4 CORCEPT THERAPEUTICS For: Apr 01 Filed by: Guyer William
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.